Abstract
Eight weeks of treatment with rifampin-streptomycin sterilizes Mycobacterium ulcerans infection in mice. Because the bactericidal activity against M. ulcerans of the combination rifampin-moxifloxacin, rifampin-clarithromycin, or moxifloxacin-clarithromycin was similar to that of rifampin-streptomycin, these combinations might be considered as alternative, orally administered combined regimens for treatment of Buruli ulcer in humans.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Anti-Bacterial Agents / therapeutic use*
-
Antibiotics, Antitubercular / therapeutic use
-
Aza Compounds / therapeutic use
-
Clarithromycin / therapeutic use
-
Colony Count, Microbial
-
Drug Combinations
-
Female
-
Fluoroquinolones
-
Foot / microbiology
-
Mice
-
Mice, Inbred BALB C
-
Moxifloxacin
-
Mycobacterium Infections, Nontuberculous / drug therapy*
-
Mycobacterium Infections, Nontuberculous / microbiology
-
Mycobacterium ulcerans*
-
Quinolines / therapeutic use
-
Rifampin / therapeutic use
-
Streptomycin / therapeutic use
Substances
-
Anti-Bacterial Agents
-
Antibiotics, Antitubercular
-
Aza Compounds
-
Drug Combinations
-
Fluoroquinolones
-
Quinolines
-
Clarithromycin
-
Moxifloxacin
-
Rifampin
-
Streptomycin